By Regenerative Medicine China · Published and sources checked · Patient information. Individual treatment and study eligibility require the responsible clinical team’s assessment.
Does a KRAS G12D and HLA-C*08:02 match mean TCR-T treatment is available in Shanghai?
No. This combination can match the biological target of an investigational TCR-T product, but it does not establish eligibility or local access. As checked on September 27, 2026, the Shanghai IX001 study NCT06487377 is withdrawn. The NT-112 study NCT06218914 lists United States sites.
Why both results matter
KRAS G12D describes a particular alteration in the tumor. HLA-C*08:02 describes an immune-system molecule involved in displaying protein fragments to T cells. The investigational product NT-112 uses a receptor designed for this particular KRAS/HLA pairing. A KRAS result alone does not supply the HLA result. NCI describes NT-112 and its target.
Keep the complete laboratory reports. A short message saying “KRAS positive” or “HLA positive” loses the specificity needed for a useful research inquiry. Ask the study team whether it accepts the existing tests or requires its own confirmation.
TCR-T and CAR-T are different approaches
TCR-engineered T cells can recognize fragments from an intracellular target when displayed by the matching HLA molecule. Conventional CAR-T cells generally recognize targets on the cell surface through a different engineered receptor. Both modify immune cells, but their target requirements differ. The pancreatic TCR-T report and NCI's CAR-T explanation describe these mechanisms. An offer labeled only “CAR-T for pancreatic cancer” does not identify a G12D/C*08:02 TCR-T product.
What the published G12D evidence actually showed
A 2022 report described a patient with metastatic pancreatic cancer who received genetically modified autologous T cells targeting KRAS G12D through HLA-C*08:02. The reported RECIST partial response was 72% and remained ongoing at six months. This was an individual outcome, not a 72% chance of benefit.
The same report discussed another treated patient whose disease progressed and who died six months after therapy. That patient experienced grade 3 cytokine release syndrome and a grade 2 neurotoxic event; manufacturing and preconditioning differed. These observations support further investigation but cannot establish a reliable response rate, survival advantage or cure probability. Read the complete NEJM report.
How to interpret newer Shanghai research
A 2026 Shanghai study reported five patients treated with TCR-T directed at KRAS G12V and HLA-A*11:01. One complete response lasted 5.5 months; two patients had short-term stable disease. Repeat infusions produced no clinical responses, and the most frequent severe adverse events were blood-related toxicities attributed to lymphodepletion. This small, single-arm study concerns a different mutation/HLA pair. Its findings cannot be used as evidence for G12D/C*08:02 treatment outcomes. Xu and colleagues, Molecular Therapy, 2026.
What the current trial records say
The Shanghai Pudong IX001 study, NCT06487377, previously listed relevant KRAS and HLA combinations. Its September 2, 2026 update records withdrawn status, sponsor discretion as the reason, zero enrolled participants and no patients dosed. It is not a current enrollment route.
NCT06218914, updated September 25, 2026, lists recruiting status and United States sites. Its NT-112 arm targets G12D/C*08:02; another arm targets different HLA alleles. A United States research listing does not establish availability in Shanghai. No current Shanghai access for this exact pairing was verified in the records reviewed.
A biological match still requires clinical screening
The NT-112 master protocol also specifies disease and prior-treatment requirements, measurable disease and an ECOG performance status of 0 or 1, with further exclusions. Matching the two laboratory results therefore addresses only part of screening. The study team must review the full history and current condition. See the current eligibility criteria.
Ask which arm is being considered, whether it has an available place, and what remains unresolved after record review. A preliminary reply should distinguish a possible match from an invitation for formal screening. Neither response promises that cells can be manufactured, treatment can proceed or the cancer will respond.
A useful next conversation
Bring both complete reports to the treating oncologist and discuss how a research inquiry fits with current care. Prepare a brief treatment timeline and request a written response tied to a named protocol. NCI recommends comparing diagnosis and health information with trial requirements, then contacting the study team. NCI's trial-search guide.
Do not change prescribed treatment merely to pursue an online listing. Ask the treating and research teams to agree on any proposed timing changes. A dated, specific answer is more useful than a general assurance that a city or institution offers advanced cell therapy.
Prepare for your review
- Exact KRAS variant and full HLA allele report
- Named cell product, protocol identifier and current study arm
- Dated confirmation of site status and screening availability
- Written list of remaining clinical and laboratory requirements
Common questions
Is the reported 72% a response rate?
No. It describes the reported degree of RECIST tumor reduction in one patient. It does not estimate an individual patient's probability of responding.
Is IX001 currently recruiting in Shanghai?
The NCT06487377 record checked on September 27, 2026 is withdrawn. An older recruiting listing should not be used to plan access.
Can the G12V Shanghai results be applied to G12D?
The mutation and HLA pairing differ. The G12V/HLA-A*11:01 findings do not establish results for G12D/HLA-C*08:02.
Does a biomarker match guarantee acceptance?
No. The research team must assess all protocol requirements and current study capacity before deciding whether formal screening is appropriate.
Sources and evidence boundaries
- Leidner et al., NEJM 2022: pancreatic KRAS G12D TCR gene therapy
- NCI Drug Dictionary: NT-112
- NCI: CAR T Cells—Engineering Immune Cells to Treat Cancer
- Xu et al., Molecular Therapy 2026: KRAS G12V phase 1/2 study
- ClinicalTrials.gov: IX001, NCT06487377 (withdrawn)
- ClinicalTrials.gov: KRAS TCR-T master protocol, NCT06218914
- NCI: Steps to Find a Clinical Trial
Registry status and local access can change. A public listing, molecular match or source citation is not a hospital partnership, a reserved place or confirmation of eligibility. Published research and overseas approvals should be interpreted in their stated setting. This guide does not present an RMC patient outcome.